[Federal Register Volume 79, Number 22 (Monday, February 3, 2014)]
[Notices]
[Page 6204]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-02155]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0124]


Science Board to the Food and Drug Administration: Request for 
Nominations

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting 
nominations to serve on the Science Board to FDA (Science Board).
    FDA seeks to include the views of women and men, members of all 
racial and ethnic groups, and individuals with and without disabilities 
on its advisory committees and, therefore, encourages nominations of 
appropriately qualified candidates from these groups.

DATES: Nominations received on or before March 5, 2014, will be given 
first consideration for membership on the Science Board. Nominations 
received after March 5, 2014 will be considered for nomination to the 
Board should nominees still be needed.

ADDRESSES: You may submit your information by logging into the FDA 
advisory Committee Membership Nomination Portal: https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or by mail 
to Advisory Committee Oversight and Management Staff, 10903 New 
Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993-0002. 
Information about becoming a member on an FDA advisory committee can 
also be obtained by visiting FDA's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm.

FOR FURTHER INFORMATION CONTACT: Martha Monser, Office of the Chief 
Scientist, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 32, Rm. 4286, Silver Spring, MD 20993-0002, 301-796-4627, email: 
[email protected].

SUPPLEMENTARY INFORMATION: FDA is requesting nominations to the Science 
Board. The Science Board will meet approximately three times a year. 
All meetings will be announced in the Federal Register at least 15 days 
prior to each public meeting.

I. General Function of the Committee

    The Science Board shall provide advice primarily to the 
Commissioner and other appropriate officials on specific complex 
scientific and technical issues important to FDA and its mission, 
including emerging issues within the scientific community. 
Additionally, the Science Board will provide advice that supports the 
Agency in keeping pace with technical and scientific developments, 
including in regulatory science; and input into the Agency's research 
agenda; and on upgrading its scientific and research facilities and 
training opportunities. It will also provide, where requested, expert 
review of Agency sponsored intramural and extramural scientific 
research programs.

II. Desired Expertise

    FDA is specifically seeing persons knowledgeable in the fields of 
food science, safety, and nutrition; chemistry; pharmacology; 
translational and clinical medicine and research; toxicology; 
biostatistics; medical devices; imaging; robotics; cell and tissue 
based products; regenerative medicine; public health and epidemiology; 
international health and regulation; product safety; product 
manufacturing sciences and quality; and other scientific areas relevant 
to FDA regulated products such as systems biology, informatics, 
nanotechnology, combination products and relevant areas of behavioral 
and social science. Members shall be chosen from academia and industry. 
The Science Board may also include technically qualified federal 
members.

III. Nomination Procedures

    Any interested person may nominate one or more qualified 
individuals for membership on the Science Board. Self-nominations are 
also accepted. Nominations must include a current, complete resume or 
curriculum vitae for each nominee, including a current business address 
and/or home address, telephone number, and email address if available. 
Nominations must also acknowledge that the nominee is aware of the 
nomination unless self-nominated. FDA will ask potential candidates to 
provide detailed information concerning such matters related to 
financial holdings, employment, and research grants and/or contracts to 
permit evaluation of possible sources of conflicts of interest.
    This notice is issued under the Federal Advisory Act (5 U.S.C. app. 
2) and 21 CFR part 14, relating to advisory committees.

    Dated: January 29, 2014.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2014-02155 Filed 1-31-14; 8:45 am]
BILLING CODE 4160-01-P